Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | Looking forward to EHA 2022: updates in multiple myeloma

Kwee Yong • 14 May 2022
EHA 2022
Multiple Myeloma

Kwee Yong, PhD, FRCP, FRCPath, University College London, London, UK, briefly highlights some of the exciting topics to be discussed in the field of myeloma at EHA 2022, including updates in immunotherapies and treatment approaches, and clinical trial data. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

More from Kwee Yong

Highlights from IMS 2025: progress in the understanding and treatment of precursor conditions 2:24
Highlights from IMS 2025: progress in the understanding and treatment of precursor conditions
Kwee Yong • 19 Sep 2025
COSMOS: studying the biology of SMM through longitudinal monitoring of patients 0:55
COSMOS: studying the biology of SMM through longitudinal monitoring of patients
Kwee Yong • 27 Sep 2024
The biological and psychological uncertainties in precursor disease 3:34
The biological and psychological uncertainties in precursor disease
Kwee Yong • 27 Sep 2024
The future of managing precursor conditions 1:05
The future of managing precursor conditions
Kwee Yong • 27 Sep 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals